Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 May;93(5):621-5.
doi: 10.1136/hrt.2006.097360. Epub 2006 Nov 29.

Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect

M D'Alto  1 , C D Vizza, E Romeo, R Badagliacca, G Santoro, R Poscia, B Sarubbi, M Mancone, P Argiento, F Ferrante, M G Russo, F Fedele, R Calabrò
Affiliations

Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect

M D'Alto et al. Heart. 2007 May.

Abstract

Background: Oral bosentan is an established treatment for pulmonary arterial hypertension (PAH).

Objective: To evaluate safety, tolerability, and clinical and haemodynamic effects of bosentan in patients with PAH related to congenital heart disease (CHD).

Patients: 22 patients with CHD related PAH (8 men, 14 women, mean (SD) age 38 (10) years) were treated with oral bosentan (62.5 mg x 2/day for the first 4 weeks and then 125 mg x 2/day).

Main outcome measures: Clinical status, liver enzymes, World Health Organisation (WHO) functional class, resting oxygen saturations and 6-min walk test (6MWT) were assessed at baseline and at 1, 3, 6, and 12 months. Haemodynamic evaluation with cardiac catheterisation was performed at baseline and at 12 month follow-up.

Results: 12 patients had ventricular septal defect, 5 atrioventricular canal, 4 single ventricle, and 1 atrial septal defect. All patients tolerated bosentan well. No major side effects were seen. After a year of treatment, an improvement was seen in WHO functional class (2.5 (0.7) v 3.1 (0.7); p<0.05), oxygen saturation at rest (87 (6%) v 81 (9); p<0.001), heart rate at rest (81 (10) v 87 (14) bpm; p<0.05), distance travelled in the 6MWT (394 (73) v 320 (108) m; p<0.001), oxygen saturation at the end of the 6MWT (71 (14) v 63 (17%); p<0.05), Borg index (5.3 (1.8) v 6.5 (1.3); p<0.001), pulmonary vascular resistances index (14 (9) v 22 (12) WU m(2); p<0.001), systemic vascular resistances index (23 (11) v 27 (10) WU.m(2); p<0.01), pulmonary vascular resistances index/systemic vascular resistances index (0.6 (0.5) v 0.9 (0.6); p<0.05); pulmonary (4.0 (1.3) v 2.8 (0.9) l/min/m2; p<0.001) and systemic cardiac output (4.2 (1.4) v 3.4 (1.1) l/min/m2; p<0.05).

Conclusions: Bosentan was safe and well tolerated in adults with CHD related PAH during 12 months of treatment. Clinical status, exercise tolerance, and pulmonary haemodynamics improved considerably.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

References

    1. MacMahon B, McKeown T, Record R G. The incidence and life expectation of children with heart disease. Br Heart J 195315121–129. - PMC - PubMed
    1. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. BMJ 195846755–762. - PMC - PubMed
    1. Farber H W, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 20043511655–1665. - PubMed
    1. Daliento L, Somerville J, Presbitero P.et al Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998191845–1855. - PubMed
    1. Galie N, Torbicki A, Barst R.et al Guidelines on diagnosis and treatment of PAH. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004252243–2278. - PubMed

MeSH terms